Olanzapine for managing side effects from tyrosine-kinase inhibitors

• Published in: Journal of clinical oncology Vol. 43; no. 5_suppl; p. 524
• Main Authors: Muniz, Miguel, Peskey, Candy, Jatoi, Aminah, Ruddy, Kathryn Jean, Orme, Jacob, Pagliaro, Lance C., Quevedo, Fernando, Costello, Brian Addis, Megan, Spychalla, Heath, Elisabeth I., Zakharia, Yousef, Singh, Parminder, Riaz, Irbaz Bin, Cathcart-Rake, Elizabeth Jane, D'Andre, Stacy D., Loprinzi, Charles L., Childs, Daniel S
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 10.02.2025

524Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but TKIs cause bothersome side effects that frequently necessitate dose reductions or treatment holds. Olanzapine has been useful for palliating sympto...